An Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Dexpramipexole (BIIB050) in Subjects With Amyotrophic Lateral Sclerosis

Trial Profile

An Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Dexpramipexole (BIIB050) in Subjects With Amyotrophic Lateral Sclerosis

Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Dexpramipexole (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions; Registrational
  • Acronyms ENVISION
  • Sponsors Biogen; Knopp Biosciences
  • Most Recent Events

    • 01 Feb 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 08 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 11 Sep 2012 Planned End Date is 1 Jan 2016, according to Clinicaltrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top